Harmony Biosciences (HRMY) Tops Q4 EPS by 44c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $1.01, $0.44 better than the analyst estimate of $0.57. Revenue for the quarter came in at $128.31 million versus the consensus estimate of $127.65 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Qualcomm investor day to detail data center plans Wednesday
• Creatd files Form S-1 and reports Q1 2026 financial results